HUM Humana Inc.

Humana Pharmacy Moves to Sustainable Packaging for Temperature-Sensitive Shipments

(NYSE: HUM), a leading health and well-being company, has announced that Humana Pharmacy customers have started receiving temperature-sensitive medications in new environmentally-friendly, cold-insulated packaging.

This press release features multimedia. View the full release here:

Humana Pharmacy has started shipping temperature-sensitive medications in this new environmentally-friendly, cold-insulated packaging. (Photo: Business Wire)

Humana Pharmacy has started shipping temperature-sensitive medications in this new environmentally-friendly, cold-insulated packaging. (Photo: Business Wire)

The packaging is made from molded biodegradable expanded polystyrene (EPS) resins, which means it is designed to decompose more than 90% over four years in most landfills. Additionally, inside each new package, customers will now find long-lasting refrigerant gel packs, which are filled with a non-toxic biodegradable gel that can be washed down the kitchen sink.

“At Humana, we recognize the undeniable link between our physical health and the health of the environment. We have a strong commitment to environmental sustainability and are investing our time and resources to help make a difference for our planet,” said Michael Taday, Humana Pharmacy President of Prescription Home Delivery, Retail Pharmacy, and OTC. “Many of our Humana Pharmacy customers receive medications that require storage at a certain temperature range, and we look forward to providing our customers with this new eco-friendly packaging.”

Customers recently started receiving the new packaging.

About Humana

Humana Inc. is committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well-being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large.

To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools – such as in-home care, behavioral health, pharmacy services, data analytics and wellness solutions – combine to produce a simplified experience that makes health care easier to navigate and more effective.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at , including copies of:

  • Annual reports to stockholders
  • Securities and Exchange Commission filings
  • Most recent investor conference presentations
  • Quarterly earnings news releases and conference calls
  • Calendar of events
  • Corporate Governance information

EN
17/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Humana Inc.

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: June 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 17, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Humana Inc: 1 director

Two Directors at Humana Inc bought 7,133 shares at between 0.000USD and 229.247USD. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch